Progentos Therapeutics
Watertown, US · Founded 2023 · Delaware corporation · 6 known investors
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells. The company targets the significant unmet need for remyelinating treatments that could repair damage caused by MS and potentially restore lost function.
Founders & leadership
DH
Dmitrij HristodorovNamed on SEC filing
CL
Christopher LooseNamed on SEC filing
SM
Sanjay MagaviNamed on SEC filing
MT
Marc-Olivier TurgeonNamed on SEC filing
Board
AR
DJ
CB
Investors · 6
Reported raises · per SEC filings
Form D private placements$68.6M disclosed across 1 round · 2024
▶$68.6MraisedMay 2024 · 39 investors · OtherRule 506(b)
▶$68.6MraisedMay 2024 · 39 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Aleks Radovic-MorenoDirector
- Dmitrij HristodorovDirector
- Dan JanneyDirector
- Christopher LooseExecutive Officer, Director
- Cassidy BlundellDirector
- Sanjay MagaviExecutive Officer
- Marc-Olivier TurgeonDirector
- Offering amount
- $68.6M
- Amount sold
- $68.6M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapRegeneron NASDAQ: REGN www.regeneron.com4 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Precigen4 shared keywordsPrecigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.
PepGen4 shared keywordsPepGen develops disease-modifying therapeutics aimed at the underlying causes of serious genetic neuromuscular and neurological diseases. The company is building a pipeline of oligonucleotide-based treatments for these conditions.
Forbion3 shared keywordsForbion is a global venture capital firm that invests in biotech innovations and sustainable solutions focused on human and planetary health. It integrates ESG principles into its investments, targeting patient impact, societal benefits, and sustainability.
Companies competing with Progentos Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Progentos Therapeutics do?
- Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells. The company targets the significant unmet need for remyelinating treatments that could repair damage caused by MS and potentially restore lost function.
- Who are Progentos Therapeutics's investors?
- Progentos Therapeutics's investors include Alta Partners, Longwood Fund, Mission Biocapital, Dolby Family Ventures, Forbion, Service Provider Capital.
- How much funding has Progentos Therapeutics raised?
- Progentos Therapeutics has disclosed $68.6M raised across 1 round.
- Where is Progentos Therapeutics headquartered?
- Progentos Therapeutics is headquartered in Watertown, US.